Abstract: Peptide compounds and their use in treating diseases and disorders that cause, are caused by, or are characterized by cellular oxidative stress.

Abstract: A multispectral sensing device includes a first die, including silicon, which is patterned to define a first array of sensor elements, which output first electrical signals in response to optical radiation that is incident on the device in a band of wavelengths less than 1000 nm that is incident on the front side of the first die. A second die has its first side bonded to the back side of the first die and includes a photosensitive material and is patterned to define a second array of sensor elements, which output second electrical signals in response to the optical radiation that is incident on the device in a second band of wavelengths greater than 1000 nm that passes through the first die and is incident on the first side of the second die. Readout circuitry reads the first electrical signals and the second electrical signals serially out of the device.

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Abstract: Peptide compositions and their use for inhibiting tumor necrosis factor, pro-inflammatory cytokines and other inflammatory response mediators.

Abstract: Methods of using anti-integrin peptides for a) improving best corrected visual acuity of an eye of a subject suffering from non-exudative age related macular degeneration and/or b) improving color vision in an eye of a subject suffering from impaired color vision and/or for treatment of other disorders.

Abstract: Peptide therapies to improve, or lessen impairment of, mitochondrial function. These therapies are useable to disorders causing, caused by, contributing to, or related to mitochondrial dysfunction, such as neurodegeneration, metabolic disease, congestive heart failure, chronic heart failure with reduced ejection fraction, chronic heart failure with preserved ejection fraction, Barth syndrome, kidney disease and kidney failure due to percutaneous renal angiography for renal artery stenosis, impaired skeletal muscle function in the elderly, primary muscle mitochondrial myopathy and neuropathy, ischemia-reperfusion injury and protozoal infections, peripheral neuropathy, dermatologic disorders and inflamed hemorrhoids.

Abstract: Nonnatural peptides and their methods of use in human or non-human animal subject to cause an effect such as: nuroprotection, protecting against or lessening nerve impairment or damage, treating glaucoma, treating age-related macular degeneration or other inherited or acquired retinal degenerations, enhancing retinal tissue repair, enhancing retinal regenerative therapy through activation of innate immune cells or treating inherited or acquired retinal degeneration.

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Abstract: Peptide compositions and methods for inhibiting neovascularization or development of pathological or aberrant blood vessels in human or other animal subjects.

Abstract: Peptide compositions and methods for inhibiting neovascularization or development of pathological or aberrant blood vessels in human or other animal subjects.

Abstract: Compositions and methods for treating Dry Eye in a human or non-human animal subject wherein an effective amount of a pharmaceutical composition comprising an anti-integrin peptide is administered to an eye of the subject. The anti-integrin peptide may comprise a peptide which causes at least one effect selected from: reduced expression of the Complement 3 Receptor (Integrin ?M?2); reduced leucocyte adhesion; and reduced trans-endothelial leucocyte migration. The peptide may comprises Risuteganib.

Abstract: Compositions and methods for treating and preventing arthropod infestation are disclosed. A method of treating an arthropod infestation in a subject in need thereof, the method comprising administering topically to the subject an effective amount of either an insecticidal composition consisting essentially of at least one essential oil and a pentacyclosiloxane or an insecticidal composition comprising at least one essential oil, a pentacyclosiloxane, and a mineral oil.

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Abstract: Compositions and methods for treating and preventing arthropod infestation are disclosed. A method of treating an arthropod infestation in a subject in need thereof, the method comprising administering topically to the subject an effective amount of either an insecticidal composition consisting essentially of at least one essential oil and a pentacyclosiloxane or an insecticidal composition comprising at least one essential oil, a pentacyclosiloxane, and a mineral oil.

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Abstract: Peptide compositions and methods for inhibiting neovascularization or development of pathological or aberrant blood vessels in human or other animal subjects.

Abstract: Nonnatural peptides and their methods of use in human or non-human animal subject to cause an effect such as: nuroprotection, protecting against or lessening nerve impairment or damage, treating glaucoma, treating age-related macular degeneration or other inherited or acquired retinal degenerations, enhancing retinal tissue repair, enhancing retinal regenerative therapy through activation of innate immune cells or treating inherited or acquired retinal degeneration

Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

Abstract: Compositions and methods for treating and preventing arthropod infestation are disclosed. A method of treating an arthropod infestation in a subject in need thereof, the method comprising administering topically to the subject an effective amount of either an insecticidal composition consisting essentially of at least one essential oil and a pentacyclosiloxane or an insecticidal composition comprising at least one essential oil, a pentacyclosiloxane, and a mineral oil.

Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).